Therapeutics
Increase your drug’s likelihood of progressing through development to the clinic.
Collaborate with us to access our state-of-the-art research facilities in Stevenage, gain valuable support from our highly experienced scientists, and leverage our longstanding drug discovery expertise in small molecules and biologics.
We can also offer personalised strategic advice on potential development routes to market and facilitate connections with commercial partners.
Our track record
30 years’
experience in drug discovery
Humanised antibodies for
5 licenced medicines
Our areas of expertise
Antibody technologies
We work closely with you to develop your antibodies and accelerate them to the clinic.
Antibody humanisation
We’ve helped to humanise nearly 100 therapeutic monoclonal antibodies, leading to 5 licensed drugs, a number of patents and several publications.
Antibody discovery
We use innovative single B-cell technologies and clinically-validated transgenic Kymouse platform to generate fully human therapeutic antibodies.
Small molecule drug discovery
We use our compound libraries, external libraries and structure-guided discovery.
Targeted protein degradation*
We’re building our capacity here, with a focus on PROTACs and E3 ligases to degrade target proteins that aren’t classically targetable by small molecule inhibitors.
Assay development
Supporting target validation, drug discovery and characterisation.
Structural biology / in silico screening
Including machine learning-based methods to improve drug design.
Medicinal chemistry
* capability or platform in development
We are looking for research projects related to our Translational Challenges that demonstrate:
- Novel therapeutic targets
- New approaches to modulating a known disease target
- Strong evidence linking the target to human disease
- Evidence from model systems showing that modulation of the target has a therapeutically relevant effect
- Disease biology expertise, such as access to enabling assays, reagents and disease models
- New technologies that could speed up drug discovery or allow us to tackle diseases and targets that can’t currently be treated
Who to contact
-
Volker Germaschewski
Read bio: Volker Germaschewski
Other ways we can support you
Antibody discovery
Innovative single B-cell technologies and clinically-validated platform to generate fully human therapeutic antibodies.
Diagnostics development
We support all stages of diagnostic development, from assay design through to clinical validation.
Targeted protein degradation
PROTACs and alternative E3 ligases to degrade target proteins that aren’t classically targetable by small molecule inhibitors.
Commercialisation advice
Support your technology transfer to progress your work towards commercially viable products.
Contact us
In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. If you would like your data to be removed, please email dataprivacy@lifearc.org.
Please see our Privacy Policy in relation to the personal data you submit to us through this page.
Latest news
-
LifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases
Read more: LifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases -
First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases
Read more: First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases -
New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya
Read more: New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya